MAIA Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAIA research report →
Price Chart
About the company
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response.
- CEO
- Vlad Vitoc
- IPO
- 2022
- Employees
- 13
- HQ
- Chicago, IL, US
Get TickerSpark's AI analysis on MAIA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $72.35M
- P/E
- -1.88
- Fwd P/E
- 1.07
- PEG
- 0.13
- P/S
- 0.00
- P/B
- 3.50
- EV/EBITDA
- -2.62
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -211.15%
- ROIC
- -131.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-24,269,686
- Net Income
- $-22,396,172+3.7%
- EPS
- $-0.70+33.3%
- OCF Growth
- -20.0%
- FCF Growth
- -20.0%
- 52W High
- $3.19
- 52W Low
- $0.87
- 50D MA
- $1.32
- 200D MA
- $1.49
- Beta
- 0.28
- RSI (14)
- 40
- Avg Volume
- 544.68K
No earnings-call transcripts are available for MAIA yet.
- Free Float
- 131.6%
- Shares Outstanding
- 60.80M
- Float Shares
- 79.99M
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Solas Capital Management, LLC | 3.03M | ▼ 1.27M |
| Alyeska Investment Group, L.P. | 2.50M | 0 |
| Vanguard Capital Management LLC | 2.41M | ▲ 339.23K |
| Vanguard Group Inc | 1.15M | ▲ 51.69K |
| 683 Capital Management, LLC | 1.07M | 0 |
| Centric Wealth Management | 796.72K | 0 |
| Cable Car Capital LLC | 514.58K | ▼ 133.92K |
| Geode Capital Management, LLC | 504.38K | ▲ 143.90K |
| Bleichroeder LP | 500.00K | 0 |
| Renaissance Technologies LLC | 415.70K | ▲ 415.70K |
| Blackrock, Inc. | 403.01K | ▲ 275.03K |
| Vanguard Fiduciary Trust Co | 336.69K | ▲ 137.37K |
Held by 27 ETFs
Biggest fund positions in MAIA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Theagene Jean-Manasse | other | 32,012 |
| Sep 30, 26 | Smith Stan | other | 38,871 |
| Sep 30, 26 | Luput Cristian | other | 33,536 |
| Sep 30, 26 | Louie Ngar Yee | other | 39,634 |
| Sep 30, 26 | Guerrero Ramiro | other | 32,012 |
| Sep 30, 26 | CHAOUKI STEVEN M | other | 32,774 |
| Sep 14, 26 | Vitoc Vlad | buy | 73,000 |
| Sep 10, 26 | Guerrero Ramiro | buy | 37,595 |
| Aug 28, 26 | Guerrero Ramiro | buy | 46,620 |
| Aug 27, 26 | Guerrero Ramiro | buy | 78,239 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MAIA coverage
Recent articles, reports, and earnings notes.
No research on MAIA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAIA report →Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
globenewswire.com · Oct 1
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest
youtube.com · Sep 28
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
globenewswire.com · Sep 23
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
globenewswire.com · Sep 22
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
globenewswire.com · Sep 16
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
globenewswire.com · Sep 15
MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding
youtube.com · Sep 11
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.